Abstract: An implantable preparation comprises a material which can be obtained from globin that has been modified, especially chemically, to be, at least partially, soluble at physiological pH. The material is biocompatible, and biodegradable in the organism. The material may be soluble at physiological pH, or insoluble at that pH. The preparation may be in the form of a solution, suspension, paste, gel, film, sponge, powder or granules, or a solid implant. The preparation can be used for the healing, protection or filling of external skin wounds, the filling of wrinkles and skin flaws, the filling of tissue, as a device for fixing prostheses or biomaterials, or as a device for preventing adhesion.

Abstract: Absorbable radiation or radiochemically sterilized medical devices, including sutures, whose breaking strength and absorption profile can be modulated by controlling the total dose received during sterilization are disclosed.

Abstract: The present invention relates to a method of treating a wound and an apparatus for promoting wound healing. An enclosure is applied over the site of a wound and filled with a physiologically acceptable rinse solution. The physiologically acceptable rinse solution treats the wound and can promote the growth of tissue cells in the wound. Following exposure to the wound, the physiologically acceptable rinse solution is analyzed by a data sensor to determine the wound bed biology.

Abstract: New topical medicaments are provided. The medicaments comprise menthol and camphor, preferably provided as part of a base gel, supplemented with potassium and a source of oxygen. The most preferred base gel is sold under the name SOMBRA, while the most preferred source of oxygen is a chlorite (e.g., sodium chlorite) and/or spirulina. The medicaments provide high metabolic activities and sustain those activities over prolonged periods of time, thus being useful for treating a large variety of ailments, including diabetic neuropathy, post hepatic neuralgia, scleroderma, psoriasis, strain, spasticity, headaches, neuropathy secondary to drugs, peripheral neuropathy, leg pain, muscle cramps, muscle aches and pains, bruise, sinusitis, sprain, arthritis, joint pain (arthralgia), and edema.

Abstract: Gelled biopolymer based foams are disclosed. The gelled foams comprise a cross-linked biopolymer, preferably alginate; optionally, a foaming agent such as hydroxy propyl methyl cellulose; and a plasticizer, preferably glycerin sorbitol, or a mixture thereof, that forms the predominant portion of the gelled foam. The foams are soft and pliable and have high absorbency. They are used as wound dressing materials, controlled release delivery systems, cell culture, barrier media for preventing tissue adherence, and bioabsorbable implants. They also have various personal care applications, especially in oral hygiene, and can be used in food applications.

Abstract: Gelled biopolymer based foams are disclosed. The gelled foams comprise a cross-linked biopolymer, preferably alginate; optionally, a foaming agent such as hydroxy propyl methyl cellulose; and a plasticizer, preferably glycerin sorbitol, or a mixture thereof, that forms the predominant portion of the gelled foam. The foams are soft and pliable and have high absorbency. They are used as wound dressing materials, controlled release delivery systems, cell culture, barrier media for preventing tissue adherence, and bioabsorbable implants. They also have various personal care applications, especially in oral hygiene, and can be used in food applications.

Abstract: Gelled biopolymer based foams are disclosed. The gelled foams comprise a cross-linked biopolymer, preferably alginate; optionally, a foaming agent such as hydroxy propyl methyl cellulose; and a plasticizer, preferably glycerin sorbitol, or a mixture thereof, that forms the predominant portion of the gelled foam. The foams are soft and pliable and have high absorbency. They are used as wound dressing materials, controlled release delivery systems, cell culture, barrier media for preventing tissue adherence, and bioabsorbable implants. They also have various personal care applications, especially in oral hygiene, and can be used in food applications.

Abstract: Gelled biopolymer based foams are disclosed. The gelled foams comprise a cross-linked biopolymer, preferably alginate; optionally, a foaming agent such as hydroxy propyl methyl cellulose; and a plasticizer, preferably glycerin sorbitol, or a mixture thereof, that forms the predominant portion of the gelled foam. The foams are soft and pliable and have high absorbency. They are used as wound dressing materials, controlled release delivery systems, cell culture, barrier media for preventing tissue adherence, and bioabsorbable implants. They also have various personal care applications, especially in oral hygiene, and can be used in food applications.

Abstract: Pharmaceutically acceptable hydrogel polymers of natural, recombinant or synthetic origin, or hybrids thereof, are introduced in a dry, less hydrated, or substantially deswollen state and rehydrate in a physiological environment to undergo a volumetric expansion and to affect sealing, plugging, or augmentation of tissue, defects in tissue, or of organs. The hydrogel polymers may deliver therapeutic entities by controlled release at the site. Methods to form useful devices from such polymers, and to implant the devices are provided.

Abstract: The present disclosure provides tissue supports which may be utilized by themselves or in combination with other tissue closure means to enhance wound closure and healing. The tissue supports are made of a material which shrinks upon application of heat or light to further support the tissue and/or wound to which it is applied.

Abstract: Precut, user-shapeable, resorbable polymer micro-membranes having cusped orifices are disclosed. The micro-membranes are constructed of resorbable polymers, which are engineered to attenuate adhesions. The membranes can formed to have very thin thicknesses, for example, thicknesses between about 0.010 mm and about 0.300 mm, while maintaining adequate strength. The membranes can be extruded from polylactide polymers having a relatively high viscosity property, can be stored in sterile packages, and can be preshaped with relatively high reproducibility during implantation procedures.

Abstract: The present invention utilizes a nano-coating of an oxide such as silica, a silicate or another effective oxide on a surface to accelerate blood clotting in mammalian animals. The hemostatic layer has a thickness that is effective for the hemostasis, yet can be made thin enough to result in a resorbable film which can either be applied to a biocompatible or resorbable device that can be used in surgical applications as well as in topical applications such as trauma.

Abstract: The present invention provides a new structure made of collagen for improving promotion of nerve tissue regeneration, curing and regeneration of a defective part of a soft biological tissue and so on without using laminin or nerve growth factor (NGF), and a member for tissue regeneration including the same. The structure made of collagen according to the present invention has a thin film multilocular formation and therefore a new structure different from a colloid form, a gel form, and a fiber form. Therefore, when the new structure made of collagen according to the present invention is used as a member for tissue regeneration, surprisingly, promotion of regeneration, shortening of a treatment period, functional recovery, or the like of bodily tissue such as nerve tissue, subdermal tissue, submucosal tissue, membranous tissue, fat tissue, muscle tissue, skin tissue, and gingival tissue can be improved.

Abstract: A medical method and dressing for application, and maintenance of medication on healthy, damaged diseased or infected living tissue. Medication is applied to body tissue and then coated with a bioadhesive providing medication maintenance on tissue and protection from body and other liquids or abrasion thereby preventing removal of the medication during a healing or treatment process.

Abstract: A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.

Abstract: Uniform, functional polymer patches can be attached to a fraction of the surface area of living individual cells. These surface-modified cells remain viable after attachment of the functional patch. The patch does not completely occlude the cellular surface from the surrounding environment. Functional payloads carried by the patch may include, for example, drugs or other small molecules, peptides, proteins, thermally responsive polymers, and nanoparticles, or any other material that can be incorporated in a polymer patch of subcellular dimensions. The patch can include one or more polyelectrolyte multilayers (PEMs).

Abstract: The present invention relates to a multilayer structure (1) including a first upper layer (2) consisting of an organic matrix including collagen and at least a lower layer (3, 4, . . . 10) consisting of a composite matrix including hydroxylapatite and collagen. Furthermore, the present invention relates to a cartilaginous substitute including said multilayer structure (1) as well as an osteochondral substitute including said multilayer structure (1). Finally, the present invention relates to the use of said multilayer structure (1) for the preparation of said cartilaginous substitute and said osteochondral substitute for the treatment of cartilaginous defects and osteochondral defects or for the neo-formation of a cartilaginous tissue and/or a subchondral bone tissue.

Abstract: This invention provides novel nanofiber enhanced surface area substrates and structures comprising such substrates, as well as methods and uses for such substrates.

Abstract: Scientifically Modulated And Reprogrammed Treatment (SMART) Virus Fas/FasL technology is intended to terminate T-Helper cells infected with the Human Immunodeficiency Virus. The SMART-Fas/FasL Virus carrying Fas and FasL cell-surface receptors is capable of engaging a T-Helper cell infected by HIV that is expressing one or more FasL cell-surface receptors. When a T-Helper cell infected with HIV encounters a SMART-Fas/FasL Virus, the infected T-Helper cell's FasL cell-surface receptor will engage the SMART-Fas/FasL Virus's Fas receptor, then the SMART-Fas/FasL Virus's FasL will engage the infected T-Helper cell's Fas receptor, which will initiate apoptosis in the infected T-Helper cell. Given the HIV infected T-Helper cell will be triggered to die, HIV's safe haven inside the T-Helper cell will be eliminated and the threat of Acquired Immunodeficiency Syndrome caused by HIV is averted.

Abstract: Cell storage and delivery systems and methods for storing and delivering viable cells to a mammal are disclosed. The cell storage and delivery systems include a biodegradable and/or bioabsorbable fibrous matrix physically associated with viable cells to contain and release the cells at a controlled rate. The biodegradable and/or bioabsorbable matrix can be formed by electrospinning fibers of biodegradable and/or bioabsorbable fiberizable material. The methods include methods for storing viable cells and for delivering viable cells to a mammal using the cell storage and delivery system.

Abstract: The present invention relates to hemostatic fabric materials, and to the methods for making and using such materials. In particular, the present invention relates to hemostatic fabric materials made from chemically treated cellulose, where the hemostatic material can be soluble on wound surfaces.

Abstract: A nonaqueous, extrudable composition includes at least one thermoplastic polymer in an amount of more than 20 wt % of the whole composition and tobacco. An extruded bioactive product in the form of a sheet can be made by extruding or hot melt shaping a nonaqueous composition comprising at least one thermoplastic polymer and a bioactive agent, the sheet being soluble in a user's mouth and resulting in sustained release of bioactive to the user. The sheet can be in a form that may be placed in contact with the mucosa of the user, and have an average dissolution time of 5 to 50 minutes for delivering the bioactive to the user.

Abstract: (1) A tissue-covering medical material which comprises a soluble cellulose derivative having been made hardly soluble in water, which is used with a purpose of being embedded in the body or applied to the tissue, and (2) a method for producing the tissue-covering medical material as defined in (1), which comprises, as a method to make a soluble cellulose derivative hardly soluble in water, freezing and thawing an acidic solution of the soluble cellulose derivative, are provided.

Abstract: The present invention provides methods for treating and preventing benign breast disease by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with benign breast disease, this effect induces disease regression. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents formation of benign breast conditions that can lead to cancer.

Abstract: Preparations for percutaneous absorption comprising a basic drug or its salt dissolved in a liquid component and having an enhanced percutaneous absorbability and a safety to the skin, i.e., the administration site. The preparations for percutaneous absorption, preferably patches, contain a basic drug or its salt, an organic acid or its salt and a liquid component having a solubility parameter of from 7 to 13 (cal/cm3)1/2 and a have a very excellent skin permeability of the drug.

Abstract: The present invention provides a light-activated adhesive composite suitable for medical and surgical applications. The composite includes a scaffold and a light-activated adhesive, such as a laser tissue solder. The scaffold includes a biological, biocompatible, or biodegradable material, such as PLGA or SIS.

Abstract: The subject invention provides a process for preparing a porous collagen matrix from connective tissue, said process comprising: a porous structure forming step to treat said connective tissue with poring agent in situ; and a washing step to remove the impurity from said porous connective tissue thereby obtaining a porous collagen matrix.

Abstract: A novel A1-B-A2 polymer having a number average molecular weight of 10000 to 100000 is provided that has excellent bioabsorbability so as to disappear in a predetermined period of time even when embedded in a large amount in the body, has good kinetic properties, and is useful for preparing tissue anti-adhesion films. This polymer is composed of segments A1 and A2 each having at least either of modified and unmodified amino acid groups, and segment B composed of PEG having a number average molecular weight of 8000 to 50000. The polymer contains both the modified and unmodified amino acid groups, the content of the modified amino acids is 20 to 85 mol % of all the amino acids in the polymer, and segment A1 is bonded to one end of segment B and segment A2 is bonded to the other end of segment B.

Abstract: Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer such as pullulan. Edible films are disclosed that include pullulan and antimicrobially effective amounts of the essential oils thymol, methyl salicylate, eucalyptol and menthol. The edible films are effective at killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath. The film can also contain pharmaceutically active agents. Methods for producing the films are also disclosed.

Abstract: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of active drugs through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.

Abstract: A composition for delivery of a molecule into a cell is provided. The composition includes a protein transduction domain that is conjugated to the molecule which is incorporated into a multilayered film. Preferably, the protein transduction domain is a cationic protein transduction domain. More preferably, the cationic protein transduction domain is nonaarginine, and the multilayered film includes polyelectrolyte multilayers. When the composition is presented to a cell, the multilayered film dissolves or erodes in physiological media, and the molecule is delivered into the cell.

Abstract: A dressing for debridement of necrotic and non-viable tissue in a wound, wherein the dressing comprises an effective amount of one or more proteolytic enzymes incorporated in a degradable polymeric material. The dressing of the invention provides effective debridement of necrotic wounds over a prolonged period of time, as the enzymes may be released over time. As the enzymes are incorporated in the polymeric material, a high stability is achieved.

Abstract: The present invention relates to a film-forming barrier composition useful for protecting the skin from body fluids, such as urine, feces, menses. The composition comprises a skin conditioning agent, a viscosity enhancing agent and an oleophilic film-forming agent. Optionally, the lotion may comprise skin care ingredients for treating or maintaining skin health. The composition may be applied to the skin by suitable delivery vehicles, such as absorbent articles or components thereof, sheet materials, pads, bandages, sponges, foam pads, pumps, sprays, depending on the viscosity of the composition.

Abstract: An angiogenesis-promoting substrate which can be manufactured easily and in reproducible quality and which, in particular, under physiological conditions, remains stable for a specified time and yet is biocompatible and resorbable is provided, comprising a porous shaped body formed from a gelatin-containing material which is insoluble and resorbable under physiological conditions.

Abstract: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film.

Abstract: A sterile wound treatment kit includes a plastic container pouch with a sealed outer periphery which forms a sterile interior region which isolates the pouch interior from a surrounding environment. A drug absorbing medium is located within the pouch interior and initially isolated from the surrounding environment by the sealed periphery. A syringe accepting fitting is located on the pouch for discharging a treatment drug from a syringe into the pouch interior. The pouch interior is large enough to allow the drug absorbing medium to be shaken within the pouch interior once a drug is injected into the sterile interior region, whereby the drug absorbing medium will contact and evenly absorb the drug treatment. The pouch can be opened at the time of use to allow access to the drug absorbing medium so that the medium can be applied to a wound site.

Abstract: A method and composition for preventing the formation of lesions in a patient having a site of inflammation by the use of a cromolyn compound. The cromolyn compound is used with a composition containing penetrating aids.

Abstract: The invention provides a fast-dissolving or fast-disintegrating film preparation having a high proportion (i.e., at least about 40%) of active agent(s) and related methods for its preparation. In one embodiment, the active agent is a pharmaceutical and the film comprises between about 10% and about 40% pullulan as a primary or sole water-soluble polymer.

Abstract: A patch for cardiac tissue engineering includes a gel layer supported by an intermediate layer, which is attached to a reinforcement layer. These patches may be implanted in a heart to treat pediatric congenital malformations of the heart as well as adult ischemic myopathies. The gel layer may include cells such as, for example, stem cells; the intermediate layer may be biodegradable porous mesh and the reinforcement layer may be polytetrafluoroethylene. Included are methods for making patches according to the invention and for tissue engineering using patches of the invention.

Abstract: The present invention relates to medicine, more concretely to photodynamic therapy, and may be used in oncology and dermatology. A method is proposed for photodynamic therapy of pathological surface formations, which comprises sensitizing a surface of the pathological area by superposing an applicator containing 5-aminolevulinic acid, and irradiating the sensitized area with therapeutic optical radiation in the spectral range of 625-700 nm, wherewith an applicator is used which is transparent in the spectral range of at least 625-700 nm, and irradiation is carried out through the applicator. Wherewith therapeutic irradiation is carried out under control of the intensity of fluorescence of the tissues of the pathological area by irradiation of the tissues in the spectral range of 625-635 nm and measurement of the intensity of fluorescence in the range of 635-700 nm through the applicator.

Abstract: A multilayer preparation in the form of films of hydrophilic polymers for rapid release of substances present in the film layers into liquid surroundings is characterized in that adjacent layers differ from one another in that in each case one layer is soluble in a nonaqueous solvent in which the respective adjacent layer is insoluble or only slightly soluble.

Abstract: The present disclosure provides tissue supports which may be utilized by themselves or in combination with other tissue closure means to enhance wound closure and healing. The tissue supports are made of a material which shrinks upon application of heat or light to further support the tissue and/or wound to which it is applied.

Abstract: A biodegradable microfiber absorbent comprises a substantially homogeneous mixture of at least one hydrophilic polymer and at least one biodegradable polymer. The absorbent can be prepared by an electro hydrodynamic spinning of a substantially homogeneous polymer mixture. Medical dressings for burns and wounds, cavity dressings, drug delivery patches, face masks, implants, drug carriers that comprises at least one microfiber electrospun from a polymer mixture are provided. The dressings can have variable water vapor penetration characteristics and variable biodegradation times.

Abstract: Proteinaceous polymers having repetitive units from naturally occurring structural proteins are employed as backbones for functionalities for crosslinking to provide strongly adherent tissue adhesives and sealants. Particularly, block copolymers of elastin and fibroin are employed having lysine substitutions in spaced apart units, where the amino group can be crosslinked using difunctional crosslinking agents.

Abstract: A pharmaceutical composition to be externally applied as a topical preparation for treating several diseases, the composition comprising dimethylsulfoxide (DMSO) and ozone. A method for obtaining the composition by ozonizing DMSO and a method for treating diseases by applying the composition are also provided.

Abstract: A ligating band according to the present invention comprises an elastomeric layer and an inner drug releasing layer. The inner drug releasing layer includes a therapeutic agent, for example a chemotherapeutic agent for treating a mucosa, polyp or other growth. A ligating band according to the present invention also may include an inner diffusion barrier disposed between the elastomeric layer and the inner drug releasing layer, with the elastomeric layer and the inner drug releasing layer each contacting the inner diffusion barrier.

Abstract: This invention provides supplemented and unsupplemented tissue sealants as well as methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one antibody. The composition may be further supplemented with, for example, one or more analgesics, antimicrobial compositions, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.

Abstract: The specification discloses an alginate foam composition dressing which may be prepared with or without a backing. The foam dressing exhibits unique capability in including soluble or insoluble medicaments as part of the alginate foam composition, attributes not inherent in alginate dressings prepared by spinning. The dressings so prepared also eliminate the need for adhesives and secondary dressings for retaining an alginate dressing on a wound site.

Abstract: The present patent describes a biocompatible composite made of a first fibrous layer attached to a three-dimensional inter-connected open cell porous foams that have a gradient in composition and/or microstructure through one or more directions. These composites can be made from blends of absorbable and biocompatible polymers. These biocompatible composites are particularly well suited to tissue engineering applications and can be designed to mimic tissue transition or interface zones.

Abstract: The present invention provides bioerodable constructs for controlled release of bioactive materials. In a preferred mode, the constructs may be utilized adjacent to a biological surface. The constructs are based on a blend of two or more poly(ester-amide) polymers (PEA). Such polymers may be prepared by polymerization of a diol (D), a dicarboxylic acid (C) and an alpha-amino acid (A) through ester and amide links in the form (DACA)n. An example of a (DACA)n polymer is shown below in formula II. Suitable amino acids include any natural or synthetic alpha-amino acid, preferably neutral amino acids.